PAP
CMPX icon

Persistent Asset Partners’s Compass Therapeutics CMPX Stock Holding History

Persistent Asset Partners’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-459
Closed -$13.1K – 191
2025
Q1 		$13.1K Buy
+459
New +$1.22K 0.01% 151

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Persistent Asset Partners's CMPX Position: Q2 2026 in Review

Persistent Asset Partners sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 72,193 shares — an estimated $382K sold.

Persistent Asset Partners first reported a position in CMPX in Q4 2025 and held it in 2 quarters. The position peaked at $382K in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Persistent Asset Partners reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 72,193 Compass Therapeutics shares in Q2 2026, an estimated $382K.
  • Persistent Asset Partners first reported a position in Compass Therapeutics in Q4 2025 and held it in 2 quarters.
  • Persistent Asset Partners's Compass Therapeutics position peaked at $382K in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.